A multi-institutional experience of autologous stem cell transplantation in North American patients with human T-cell lymphotropic virus type-1 adult T-cell leukemia/lymphoma suggests ineffective salvage of relapsed patients.

摘要

Adult T-cell leukemia/lymphoma (ATLL) is a rare T-cell neoplasm caused by the human T-cell lympho-tropic virus type-1 (HTLV-1), a retrovirus endemic in Japan, sub-Saharan Africa and the Caribbean basin. In the U.S., ATLL is primarily seen among immigrants from endemic regions. Patients with the acute and lymphomatous subtypes have the poorest prognosis, with a median survival of only 6-13 months despite aggressive combination chemotherapy [1], Without an established curative regimen, high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) has become a salvage treatment in the relapsed setting [2].